Due to lack of targetable markers (ER, PR and HER2), most cases of TNBC are considered incurable with a shorter life expectancy compared to ER, PR or HER2 positive breast cancer subtypes [72,74,75]. This evidence concerns the gene ESR1 and breast carcinoma.